StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
August 4, 2017 5:54 AM
RBC Capital downgraded Teva Pharma (NYSE: TEVA) from Outperform to Underperform with a price target of $21.00 (from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
Teva Pharma (TEVA) Granted FDA Approval of QVAR® RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol
August 7, 2017 8:01 AM
Teva Pharma (TEVA) PT Lowered to $28 at Deutsche Bank
August 4, 2017 8:41 AM
Teva Pharma (TEVA) PT Lowered to $26 at Jefferies
August 4, 2017 7:50 AM
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM
Cowen Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 5:51 AM
Teva Pharma (TEVA) PT Lowered to $23 at Piper Jaffray, Lowers EPS Estimates
August 3, 2017 2:37 PM
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
August 3, 2017 12:51 PM
UPDATE: Oppenheimer Downgrades Teva Pharma (TEVA) to Perform
August 3, 2017 9:57 AM
Teva Pharma (TEVA) Sinks 16% on Weak Results, Outlook
August 3, 2017 8:18 AM
